Skip to main content

Advertisement

SpringerLink
Log in

Biologic subtypes as a predictor of local control in patients with brain metastases from breast cancer after stereotactic radiosurgery

  • Original Research
  • Published:
Journal of Radiation Oncology

Abstract

Purpose

Biological subtypes have been strongly correlated with loco-regional recurrence after definitive treatment for localized breast cancer. Brain metastases (BM) occur in 15% of patient diagnosed with breast cancer (BC). Therefore, we sought to determine whether biologic subtype is predictive of local control (LC) in BC patients with BM treated with stereotactic radiosurgery (SRS).

Methods

This is a single-center retrospective study conducted with Institutional Review Board approval for the period January 1, 2004–December 31, 2018. Eligibility criteria included (1) histopathologic proven BC with documented biologic subtype, (2) presence of BM treated with SRS (single fraction), (3) follow-up MRIs, and (4) clinical follow-up. Patients were subdivided into three biologic subtypes: ER+/HER2- (“luminal”), HER2+, and ER-/PR-/HER2 (TN). All patients were treated with LINAC-based SRS with dose according to published guidelines. Cox proportional hazard model and Kaplan-Meier were used for statistical analysis of LC and overall survival (OS).

Results

With a median follow-up of 11.1 months, 17 BC BM in 50 consecutive patients were included in this study. The median disease-specific GPA was 2.0, and all patients received systemic chemotherapy and/or hormonal therapy. The 12-month LC rates for the entire cohort were 85%, 87%, and 49% for luminal, HER2+, and TN, respectively, with a significantly shorter time to local failure for the TN subtype (p = 0.014). The 12-month OS rates were 83%, 88%, and 80% for luminal, HER2+, and TN, respectively, with a trend toward shorter OS in the TN group.

Conclusion

This study shows that in BC patients with BM treated with SRS, biologic subtype affects LC. Consideration of radiation treatment intensification or altered fractionation to improve LC may be indicated for the TN subtype. Further multicenter studies are necessary to corroborate our results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Johnson JD, Young B (1996) Demographics of brain metastasis. Neurosurg Clin N Am 7(3):337–344

    Article  CAS  PubMed  Google Scholar 

  2. Wen PY, Loeffler JS (1999) Management of brain metastases. Oncology 13(7):941–954 57–61; discussion 61–2, 9

    CAS  PubMed  Google Scholar 

  3. Posner JB (1992) Management of brain metastases. Rev Neurol 148(6–7):477–487

    CAS  PubMed  Google Scholar 

  4. Paterson AH, Agarwal M, Lees A, Hanson J, Szafran O (1982) Brain metastases in breast cancer patients receiving adjuvant chemotherapy. Cancer 49(4):651–654

    Article  CAS  PubMed  Google Scholar 

  5. Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ (2005) Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 5(2):108–113

    Article  PubMed  Google Scholar 

  6. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22(14):2865–2872

    Article  PubMed  Google Scholar 

  7. Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22(17):3608–3617

    Article  PubMed  Google Scholar 

  8. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94(10):2698–2705

    Article  PubMed  Google Scholar 

  9. Horton JK, Jagsi R, Woodward WA, Ho A (2018) Breast cancer biology: clinical implications for breast radiation therapy. Int J Radiat Oncol Biol Phys 100(1):23–37

    Article  PubMed  Google Scholar 

  10. Howlader N, Altekruse SF, Li CI et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. Jnci-J Natl Cancer I 106(5)

  11. Jensen EV, Jordan VC (2003) The estrogen receptor: a model for molecular medicine. Clin Cancer Res 9(6):1980–1989

    CAS  PubMed  Google Scholar 

  12. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752

    Article  CAS  PubMed  Google Scholar 

  13. Breast Cancer Staging System (2018) AJCC cancer staging manual, Eight Edition

  14. Arvold ND, Oh KS, Niemierko A, Taghian AG, Lin NU, Abi-Raad RF, Sreedhara M, Harris JR, Alexander BM (2012) Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat 136(1):153–160

    Article  PubMed  Google Scholar 

  15. Millar EK, Graham PH, O'Toole SA et al (2009) Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 27(28):4701–4708

    Article  PubMed  Google Scholar 

  16. Wang YH, Yin QG, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y (2011) A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast Cancer Res Treat 130(2):489–498

    Article  PubMed  Google Scholar 

  17. Merino T, Ip T, Dominguez F et al (2018) Risk factors for loco-regional recurrence in breast cancer patients: a retrospective study. Oncotarget 9(54):30355–30362

    Article  PubMed  PubMed Central  Google Scholar 

  18. Langlands FE, Horgan K, Dodwell DD, Smith L (2013) Breast cancer subtypes: response to radiotherapy and potential radiosensitisation. Brit J Radiol 86(1023)

  19. Miller JA, Kotecha R, Ahluwalia MS, Mohammadi AM, Chao ST, Barnett GH, Murphy ES, Vogelbaum MA, Angelov L, Peereboom DM, Suh JH (2017) Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. Cancer 123(12):2283–2293

    Article  CAS  PubMed  Google Scholar 

  20. Buatti JM, Friedman WA, Meeks SL, Bova FJ (2000) RTOG 90-05: the real conclusion. Int J Radiat Oncol Biol Phys 47(2):269–271

    Article  CAS  PubMed  Google Scholar 

  21. Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, Sperduto PW, Vogelbaum MA, Radawski JD, Wang JZ, Gillin MT, Mohideen N, Hahn CA, Chang EL (2012) Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2(3):210–225

    Article  PubMed  PubMed Central  Google Scholar 

  22. Lee EW, Wei LJ, Amato DA, Leurgans S (1992) Cox-type regression-analysis for large numbers of small-groups of correlated failure time observations. Nato Adv Sci I E-App 211:237–247

    Google Scholar 

  23. Shtatland ES, Barton MB (1998) An information-gain measure of fit in PROC LOGISTIC. In: Proceedings of the Twenty-Third Annual Sas Users Group International Conference. pp 1195–9

  24. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR (1979) The natural history of breast cancer patients with brain metastases. Cancer 44(5):1913–1918

    Article  CAS  PubMed  Google Scholar 

  25. Park IH, Ro J, Lee KS, Nam BH, Kwon Y, Shin KH (2009) Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Anna Oncol 20(1):56–62

    Article  CAS  Google Scholar 

  26. Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, Lee JI, Park W, Choi DH, Huh SJ, Ahn JS, Kang WK, Park K, Im YH (2009) Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 100(6):894–900

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM (2008) Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19(7):1242–1248

    Article  CAS  PubMed  Google Scholar 

  28. Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA, Alexander BM, Lin NU, Aizer AA (2017) Brain metastases in newly diagnosed breast Cancer: a population-based study. JAMA Oncol 3(8):1069–1077

    Article  PubMed  PubMed Central  Google Scholar 

  29. Bastos DCA, Maldaun MVC, Sawaya R et al (2018) Biological subtypes and survival outcomes in breast cancer patients with brain metastases in the targeted therapy era. Neuro-Oncol Pract 5(3):161–169

    Article  Google Scholar 

  30. Suzuki S, Inoue T, Ishido K (2016) Factors influencing local tumor control after gamma knife radiosurgery for intracranial metastases from breast cancer. J Clin Neurosci 33:154–158

    Article  PubMed  Google Scholar 

  31. Dyer MA, Kelly PJ, Chen YH, Pinnell NE, Claus EB, Lee EQ, Weiss SE, Arvold ND, Lin NU, Alexander BM (2012) Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases. Int J Radiat Oncol 83(4):E479–EE86

    Article  Google Scholar 

  32. Wen Y, Dai G, Wang L, Fu K, Zuo S (2019) Silencing of XRCC4 increases radiosensitivity of triple-negative breast cancer cells. Biosci Rep 39(3)

  33. Minniti G, Scaringi C, Paolini S, Lanzetta G, Romano A, Cicone F, Osti M, Enrici RM, Esposito V (2016) Single-fraction versus multifraction (3 x 9 Gy) stereotactic radiosurgery for large ( > 2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis. Int J Radiat Oncol 95(4):1142–1148

    Article  Google Scholar 

  34. Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent M, Vogelbaum MA, Wen PY, Response Assessment in Neuro-Oncology (RANO) group (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16(6):E270–E2E8

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Mount Sinai Hospital, One Gustave L. Levy Place, Box 1236, New York, NY, 10029-6574, USA

    Lucas Resende Salgado, Andrew W. Smith, Anthony Nehlsen, Alexandra Cohen, Tzu-Chi Tseng, Michael Buckstein, Richard Bakst & Sheryl Green

  2. Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029-6574, USA

    Jung-Yi Lin & Erin Moshier

  3. Department of Neurosurgery, Mount Sinai Hospital, One Gustave L. Levy Place, New York, NY, 10029-6574, USA

    Isabelle M. Germano

Authors
  1. Lucas Resende Salgado
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew W. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anthony Nehlsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexandra Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tzu-Chi Tseng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jung-Yi Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Erin Moshier
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michael Buckstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Richard Bakst
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Isabelle M. Germano
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Sheryl Green
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lucas Resende Salgado.

Ethics declarations

Conflict of interest

Lucas Resende Salgado declares that he has no conflict of interest. Andrew W. Smith declares that he has no conflict of interest. Anthony Nehlsen declares that he has no conflict of interest. Alexandra Cohen declares that she has no conflict of interest. Tzu-Chi Tseng declares that she has no conflict of interest. Jung-Yi Lin declares that she has no conflict of interest. Erin Moshier declares that she has no conflict of interest. Michael Buckstein declares that he has no conflict of interest. Richard Bakst declares that he has no conflict of interest. Isabelle M. Germano is a Brainlab and Integra consultant, Surgical Theater, and Elminda stockholder. Sheryl Green declares that she has no conflict of interest.

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Resende Salgado, L., Smith, A.W., Nehlsen, A. et al. Biologic subtypes as a predictor of local control in patients with brain metastases from breast cancer after stereotactic radiosurgery. J Radiat Oncol 9, 67–73 (2020). https://doi.org/10.1007/s13566-020-00424-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13566-020-00424-0

Keywords

Search

Navigation